SCHEMBL13543976

SCHEMBL13543976

CC1=NC2CN(C(=O)[C@H](O)[C@@H](O)C(=O)NCC3CCN(c4ccc(F)cc4C#N)CC3)CC2C=N1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADAM17 P78536 5/20 0.43
▸ CHRM4 P08173 1/20 0.39
▸ USP30 Q70CQ3 2/20 0.35
▸ MTOR P42345 2/20 0.35
▸ RPTOR Q8N122 2/20 0.35
▸ MLST8 Q9BVC4 2/20 0.35
▸ SCN9A Q15858 2/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ RPS6KB1 P23443 2/20 0.34
▸ DPP4 P27487 1/20 0.33
▸ DPP8 Q6V1X1 1/20 0.33
▸ DPP9 Q86TI2 1/20 0.33
▸ FFAR4 Q5NUL3 1/20 0.33
▸ LDHA P00338 1/20 0.33
▸ CHRNA7 P36544 1/20 0.32
▸ GPR6 P46095 1/20 0.32
▸ PGR P06401 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8221486 0.85 ADAM17 (0.43) ADAM17CHRM4USP30MTORRPTOR
SCHEMBL12240084 0.84 ADAM17 (0.44) ADAM17CHRM4USP30MTORRPTOR
SCHEMBL8221453 0.82 ADAM17 (0.53) ADAM17CHRM4USP30MTORRPTOR
SCHEMBL8221438 0.82 ADAM17 (0.53) ADAM17CHRM4USP30MTORRPTOR
SCHEMBL8273348 0.82 ADAM17 (0.53) ADAM17CHRM4USP30MTORRPTOR
SCHEMBL8213698 0.81 ADAM17 (0.53) ADAM17CHRM4USP30MTORRPTOR
SCHEMBL8213677 0.81 ADAM17 (0.48) ADAM17CHRM4USP30SCN9ASCN5A
SCHEMBL8223463 0.81 ADAM17 (0.49) ADAM17CHRM4USP30MTORRPTOR
SCHEMBL8222728 0.81 ADAM17 (0.49) ADAM17CHRM4USP30MTORRPTOR
SCHEMBL8223432 0.80 ADAM17 (0.49) ADAM17CHRM4SCN9ASCN5AFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652020-B2 novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction SCHERING CORPORATION (US) 2010-01-26 — — US disclosed
Send feedback